Study title: An open, controlled, randomized and single-centre study to evaluate the effectiveness of a new economical schedule of rabies postexposure prophylaxis using purified chick embryo cell tissue culture (PCEC) rabies vaccine (RabipurĀ®, Behring Vaccines; now Novartis Vaccines) in the patients of 1 to 61 years of age.
| Type of medicine: Non-centrally authorised vaccines | |||||
| Therapeutic area: Virus Diseases | |||||
| Brands: Please see report | |||||
| MAH holders: Please see report | |||||
| Assessment: | |||||
| Active substance: RABIES VACCINE FOR HUMAN USE PREPARED FROM CELL CULTURE (DIPLOID CELLS) | |||||
| ATC code: J07BG01 | |||||
| Document link: | |||||
| Document date: 2014-10-07 | |||||
| Study number: 7T-301IP-A | |||||
| EudraCT number: | |||||
| Scope of study: Observational study | |||||
| Population of study subjects: | Preterm newborn Infants | Newborn infants (1 to 27 days) | Infants and toddlers (28 days to 24 months) | Children (2 to 11 years) | Adolescents (12 to 18 years) |
| - | - | - | - | - | |